Zydus Lifesciences Share Price Surges; Gets Final USFDA Approval for Verapamil Hydrochloride Extended-Release Tablets

Zydus Lifesciences has received the final nod from the US Food and Drug Administration (USFDA) for its verapamil hydrochloride extended-release tablets. As per the exchange filings, the approved strengths are 120 mg, 180 mg, and 240 mg. These tablets are prescribed to manage high blood pressure and are commonly used to lower the risk of heart-related incidents such as strokes and heart attacks. 

Generic Version to Be Produced in Baddi 

The tablets are the generic equivalent of Calan SR, a reference drug sold in the same strengths in the United States. Zydus plans to manufacture the approved product at its plant in Baddi, Himachal Pradesh. According to IQVIA MAT (September 2025), the US market for verapamil extended-release tablets was valued at $24.5 million over a 12-month period. 

This latest approval pushes Zydus’ tally to 428 final USFDA approvals, while the company has filed 487 abbreviated new drug applications (ANDAs) since it started filing in FY2003-04. 

Zydus Lifesciences Q2FY26 Earnings Results 

In Q2FY26, Zydus Lifesciences posted a consolidated net profit of ₹1,259 crore, a 39% increase from ₹911 crore reported in the same quarter last year. A large part of the increase was due to foreign exchange gains of ₹414 crore, compared with ₹45 crore a year ago. 

The company reported revenue of ₹6,123 crore, up 17% year-on-year, supported mainly by growth in the US and Indian formulations businesses. Operating profit also improved, with EBITDA rising to ₹2,014 crore, a jump of 38%, and margins increasing from 27.9% to 32.9%. 

Research and development expenses for the quarter stood at ₹482 crore, which is 7.9% of total revenue. The company continues to allocate funds to research areas involving complex generic medicines. 

Read More:  Transformers and Rectifiers India Share Price Surges Over 6%; Secures Order Worth ₹389.97 Crore from GETCO!  

Zydus Lifesciences Share Price Performance  

As of November 26, 2025, 10:15 AM, Zydus Lifesciences share price was trading at ₹937.40, a 0.96% increase from the previous closing price. 

Conclusion 

With the latest USFDA approval adding to its product portfolio and steady financial results, Zydus continues to increase the number of generic medicines supplied to the US market. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.